US drugmaker Eli Lilly starts phase 3 trial for Covid-19 antibody treatment

It will evaluate the efficacy and safety of LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19.

American pharmaceutical firm Eli Lilly and Company has announced the start of its phase 3 trial to study whether one of its experimental COVID-19 antibody treatments can prevent the virus infection in residents and staff at long-term care facilities.

LY-CoV555, the lead antibody from Lilly's collaboration with Canadian biotech AbCellera, is a neutralizing antibody against SARS-CoV-2, the virus that causes COVID-19, reports Xinhua news agency.

More than 40 per cent of coronavirus deaths in the US linked to long-term care facilities creates the urgent need for therapies to prevent COVID-19 in this vulnerable population, Eli Lilly and Company said in a release on Monday.

The first-of-its-kind study is expected to enrol up to 2,400 participants who live or work at facilities that have had a recently diagnosed case of COVID-19 and who are now at a high risk of exposure.

It will evaluate the efficacy and safety of LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19, testing whether a single dose of LY-CoV555 reduces the rate of SARS-CoV-2 infection through 4 weeks, as well as complications of COVID-19 through 8 weeks, said the company.

"COVID-19 has had a devastating impact on nursing home residents," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories, in a statement.

"We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."

--IANS

ksk/

 


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel